Skip to main content

Prof. Francesco Blasi, MD, FERS

Prof. Francesco Blasi, MD, FERS

Professor of Respiratory Medicine
Department of Pathophysiology and Transplantation,
Vice Rector for Relations with the National Health Service
University of Milan
Dean of the School of Medicine, University of Milan
Milan, Italy

Related Videos

With the understanding that the WILLOW and ASPEN trials evaluated both 10mg and 25mg daily doses of brensocatib, how do you interpret the findings and apply the FEV1 improvement results that were observed in the higher dose treatment arms?

With the understanding that the WILLOW and ASPEN trials evaluated both 10mg and 25mg daily doses of brensocatib, how do you interpret the findings and apply the FEV1 improvement results that were observed in the higher dose treatment arms?

Given the side effects and compliance profiles with brensocatib, a medication that targets a critical pathobiological process in NCFBE—neutrophil-mediated inflammation—who are the ideal candidates for this novel therapy?

Given the side effects and compliance profiles with brensocatib, a medication that targets a critical pathobiological process in NCFBE—neutrophil-mediated inflammation—who are the ideal candidates for this novel therapy?

Can you explain the importance of neutrophil-mediated inflammation as a primary driver of the pathobiology of NCFBE, and the implications of new therapeutic approaches that mitigate the destructive effects of this progressive process?

Can you explain the importance of neutrophil-mediated inflammation as a primary driver of the pathobiology of NCFBE, and the implications of new therapeutic approaches that mitigate the destructive effects of this progressive process?

Can brensocatib be used in both patients who have new onset NCFBE as well as in older patients who have longstanding NCFBE with poor prognostic factors? Did subgroup analyses from ASPEN or WILLOW provide any direction regarding this question?

Can brensocatib be used in both patients who have new onset NCFBE as well as in older patients who have longstanding NCFBE with poor prognostic factors? Did subgroup analyses from ASPEN or WILLOW provide any direction regarding this question?

Can you summarize for the clinical pulmonary, infectious disease, and primary care specialist what you see as the current evidence-based role and importance of brensocatib in the treatment of NCFBE?

Can you summarize for the clinical pulmonary, infectious disease, and primary care specialist what you see as the current evidence-based role and importance of brensocatib in the treatment of NCFBE?

What are the necessary criteria that confirm the diagnosis of NCFBE and how can we improve our clinical strategies to ensure early identification of persons with NCFBE so they can become eligible for treatment?

What are the necessary criteria that confirm the diagnosis of NCFBE and how can we improve our clinical strategies to ensure early identification of persons with NCFBE so they can become eligible for treatment?

Can you discuss the mechanism of action of DPP-1 inhibitors such as brensocatib and what clinical triggers and associated findings would provide rationale for treating patients with confirmed NCFBE with this new class of agents?

Can you discuss the mechanism of action of DPP-1 inhibitors such as brensocatib and what clinical triggers and associated findings would provide rationale for treating patients with confirmed NCFBE with this new class of agents?

Professor Blasi, can you kindly introduce yourself and share with us your role at the University of Milan and, more specifically, your clinical and investigational interests in non-cystic fibrosis bronchiectasis?

Professor Blasi, can you kindly introduce yourself and share with us your role at the University of Milan and, more specifically, your clinical and investigational interests in non-cystic fibrosis bronchiectasis?

Which ASPEN and WILLOW trial design features best help clinicians identify NCFBE patients likely to benefit from brensocatib and guide evidence-based monitoring during treatment?

Which ASPEN and WILLOW trial design features best help clinicians identify NCFBE patients likely to benefit from brensocatib and guide evidence-based monitoring during treatment?